Attached files

file filename
10-Q - FORM 10-Q - ANGIOTECH PHARMACEUTICALS INCd10q.htm
EX-10.1 - LICENSE, SUPPLY, MARKETING AND DISTRIBUTION AGREEMENT - ANGIOTECH PHARMACEUTICALS INCdex101.htm
EX-32.1 - CERTIFICATION OF CEO AND CFO PURSUANT TO SECTION 906 - ANGIOTECH PHARMACEUTICALS INCdex321.htm
EX-10.2 - AMENDMENT DATED AUGUST 9, 2009 - ANGIOTECH PHARMACEUTICALS INCdex102.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 302 - ANGIOTECH PHARMACEUTICALS INCdex312.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 302 - ANGIOTECH PHARMACEUTICALS INCdex311.htm

 

EXHIBIT 99.1

EARNINGS COVERAGE RATIO

The following consolidated financial earnings coverage ratios, calculated for the year ended December 31, 2009 and the 12-month period ended September 30, 2010, give effect to all long-term financial liabilities of the Company and the repayment, redemption or retirement thereof since such date. The earnings coverage ratios and the amount of earnings and interest expense set forth below do not purport to be indicative of the earnings coverage ratios for any future periods. The deficiency figures and coverage ratio have been calculated based on amounts reported under U.S. GAAP.

 

     Year Ended
December 31,  2009
   12-Months Ended
September 30,  2010

Earnings coverage (1)

   0.6    (0.5)

 

 

(1)

Earnings coverage ratio is equal to net loss before interest expense and income taxes divided by interest expense on all debt.

The Company’s interest expense requirements amounted to approximately $38.0 million and $36.8 million for the year ended December 31, 2009 and the 12-month period ended September 30, 2010, respectively. The Company’s net loss before income taxes and interest expense for the 12-month period ended September 30, 2010 was approximately $17.6 million, which resulted in an interest coverage deficiency of approximately $54.5 million and a negative earnings coverage ratio of 0.5. The Company’s net income before income taxes and interest expense for the year ended December 31, 2009 was approximately $21.2 million, which resulted in a positive earnings coverage ratio of 0.6.